title: Multitarget drugs: the present and the future of cancer therapy.
abstract: Target therapies for the treatment of human cancers have revolutionized the concept of oncological medicine. This type of therapeutic approach is directed to the inhibition of molecular targets that play a pivotal role in tumor progression -- such as tyrosine kinase receptors (TKIs) controlling cell proliferation and survival -- mainly by means of compounds able to block their activity. In the beginning, the aim of target therapies was specifically to hit a single molecule expressed in neoplastic cells. Now the prevailing idea is that inhibiting both cancer cells and cells of the stroma supporting the tumor would gain better results in fighting the disease. Therefore, the single-target therapy is fading in favor of a multitarget approach and the new generation of TKIs is selected on the basis of their ability simultaneously to target different molecules. This review summarizes the molecular basis of multitarget therapies and the most relevant results obtained in different cancer types.
authors.affiliation: University of Turin Medical School, Institute for Cancer Research and Treatment (IRCC), Division of Molecular Oncology, Candiolo (Torino), Italy. annalisa.petrelli@ircc.it
authors.forename: Annalisa
authors.initials: A
authors.lastname: Petrelli
authors.forename: Giorgio
authors.initials: G
authors.lastname: Valabrega
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D015195:Drug Design; D006801:Humans; D008495:Medical Oncology / Q000639:trends; D009369:Neoplasms / Q000188:drug therapy* / Q000201:enzymology; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000187:drug effects; D017154:Stromal Cells / Q000187:drug effects
chemical_list: D000970:Antineoplastic Agents; D020794:Receptor Protein-Tyrosine Kinases